Sponsors (12)
The bill trades increased safety-focused oversight and federal transparency for medication abortion (mifepristone) against substantially reduced access, higher provider costs and administrative burdens, and greater legal and reputational risks for clinicians—disproportionately affecting women in rural and underserved areas.
Women and patients will face stronger safety oversight for mifepristone through REMS certification, emphasis on monitoring for adverse effects, and (in some cases) required in-person clinical evaluation, which can improve detection and management of complications.
Congress and regulators will get more transparency about REMS enforcement (annual reporting of providers losing REMS status and a reaffirmed REMS purpose), which could improve federal oversight and inform future policy or enforcement actions.
Women—especially in rural and underserved areas—will have reduced access to medication abortion because prescriptions are limited to REMS-certified providers, telemedicine prescribing can lead to multi-year loss of certification, and providers cannot cross-state prescribe, forcing travel or delaying care.
Hospitals, clinics, and clinicians will face increased administrative burdens, costs, and potential loss of trained REMS providers (fragmenting care and reducing service capacity), which may make providers less willing or able to offer mifepristone.
Automatic public reporting of providers who lose REMS status may chill clinicians from prescribing (due to reputational risk and possible harassment), discouraging participation in care delivery.
Based on analysis of 3 sections of legislative text.
Requires in-person visits and same-state medical licensure for REMS-certified providers prescribing mifepristone or defined abortion drugs; violations trigger at least two-year REMS suspension and annual reporting.
Official title: To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
Introduced June 24, 2026 by Sheri Biggs · Last progress June 24, 2026
Requires that any health care provider certified under the FDA mifepristone REMS program must see the patient in person and hold a medical license in the patient’s state before prescribing, dispensing, or administering mifepristone or any other defined “abortion drug.” Violations cause automatic loss of REMS-certified status for at least two years and trigger an annual report to Congress listing providers who lost certification for unsafe or improper prescribing. The bill defines key terms and directs the HHS Secretary (through the FDA Commissioner) to enforce these rules.